Efficacy and Safety of Linagliptin (BI 1356) in Black/African Americans With Type 2 Diabetes With a MTT Sub-study

A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 234 participants.

Also called NCT01194830

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; double masking; primary purpose treatment
Phase
Phase 3
Enrolled
  • 234 participants (enrolled count) (from the registry)
Sponsor
Registry
  • NCT NCT01194830
Start date
(registry gives no type) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Results first posted
(from the registry)
Countries
United States (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT01194830. Randomized; double masking; primary purpose treatment. Start 2010-09 (registry gives no type); primary completion 2011-10 (actual). Results posted on 2012-10-26.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Efficacy and Safety of Linagliptin (BI 1356) in Black/African Americans With Type 2 Diabetes With a MTT Sub-study
Condition
Diabetes Mellitus, Type 2
Intervention (Drug)
Linagliptin
Intervention (Drug)
Placebo
Lead sponsor
Boehringer Ingelheim (class: industry)
Collaborator
Eli Lilly and Company (class: industry)

Record details

Record id
cardio:ct-nct01194830
Content hash
6c919dc41f51f22655b38c9fc9aba28378888da80bad376365b079dbc34dd412